Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
Holding CCCC?
Track your performance easily
CCCC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.06 - $11.88
Previous Close$5.61
Volume347.70K
Average Volume (3M)925.00K
Market Cap
$427.06M
Enterprise Value$207.46M
Total Cash (Recent Filing)$255.64M
Total Debt (Recent Filing)$67.09M
Price to Earnings (P/E)―
Beta3.29
Next Earnings
Feb 20, 2025EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding70,588,959
10 Day Avg. Volume518,170
30 Day Avg. Volume925,003
Standard Deviation0.44
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)13.48
Price to Cash Flow (P/CF)-19.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.16
Enterprise Value/Gross Profit10.00
Enterprise Value/Ebitda-3.20
Forecast
1Y Price Target
$12.00Price Target Upside98.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
C4 Therapeutics News
PremiumCompany Announcements
C4 Therapeutics Advances in Protein Degradation Therapy
PremiumCompany Announcements
C4 Therapeutics Appoints New Chief Scientific Officer
Bulls Say, Bears Say
Bulls Say
Financial ValuationCCCC remains significantly undervalued ahead of key readouts that could drive 200%+ upside vs 25-30% downside based on current valuation.
Potential Market OpportunityCFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.
Safety And EfficacyNo dose limiting toxicities or serious cutaneous/skin TRAEs (Gr3+) were observed at tested doses, and CCCC announced that 640mg BID was declared safe and will proceed to dose expansion.
Bears Say
Clinical Efficacy ConcernsMost patients exhibited stable or progressive disease, and the level of efficacy is somewhat modest.
Market SentimentGiven negative Street sentiment for disappointing updates, CCCC shares could trade down to ~$4–5 in a Bear Case scenario (no efficacy or a poor safety profile).
Partnership UncertaintyCCCC has expressed its intent to partner the cemsidomide program, but a partnership has not yet been announced.
---
Ownership Overview
8.87% Insiders
13.64% Mutual Funds
0.35% Other Institutional Investors
65.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.06 and its highest was $11.88 in the past 12 months.
What is C4 Therapeutics’s market cap?
Currently, no data Available
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 108 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.379 by $0.029.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -$0.46.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 70,588,960 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.379. Following the earnings report the stock price went down -3.617%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Among the largest hedge funds holding C4 Therapeutics’s share is RA Capital Management. It holds C4 Therapeutics’s shares valued at 23M.
---
C4 Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (98.35% Upside)
$12.00 (98.35% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 85.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
325.00%
12-Months-Change
Fundamentals
Return on Equity
-46.00%
Trailing 12-Months
Asset Growth
12.93%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
---
CCCC Stock 12 Month Forecast
Average Price Target
$12.00
▲(98.35% Upside)
Technical Analysis
Best Analysts Covering CCCC
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
+6.35%
reiterated a buy rating 5 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +6.35% per trade.
---